Description

C-Type Natriuretic Peptide (CNP) (1-22), human (TFA),a 1-22 fragment of CNP, is a natriuretic peptide receptor B (NPR-B) agonist. C-Type Natriuretic Peptide (CNP) (1-22), human (TFA) inhibits cAMP synthesis stimulated by the physiological agonists histamine and 5-HT or directly by Forskolin. CNP is a potent, endothelial-derived relaxant and growthinhibitory factor[1][2][3].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)—-C95H158F3N27O30S3—-[1]Mazarati AM, et al. ANP(1-28), BNP(1-32) and CNP(1-22) increase the severity of picrotoxin-kindled seizure syndrome in rats. Life Sci. 1993;52(3):PL19-24.|[2]Morozumi N, et al. ASB20123: A novel C-type natriuretic peptide derivative for treatment of growth failure and dwarfism. PLoS One. 2019 Feb 22;14(2):e0212680.|[3]Buckley MG, et al. Circulating C-type natriuretic peptide is increased in orthotopic cardiac transplant recipients and associated with cardiac allograft vasculopathy. Clin Sci (Lond). 2000 Nov;99(5):467-72.–1966153-17-2–2311.62–98.10–C(C(O)=O)(F)(F)F.C([C@@H]1NC(=O)[C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@@H](NC(CN)=O)CC(C)C)=O)CO)=O)CCCCN)=O)=O)CSSC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@]([C@H](CC)C)(NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)CNC1=O)[H])C2=CC=CC=C2–Metabolic Disease; Neurological Disease; Cardiovascular Disease–H2O : 2 mg/mL (ultrasonic)–Others—-Others–Peptides